Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Domenica Lorusso, MD
CONTACT
Serena Giolitto, MSc
CONTACT
Lead
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
This is an open-label, prospective, multicenter, randomized Phase II, clinical trial evaluating the efficacy and safety of Decitabine-Carboplatin combination in recurrent, platinum resistant ovarian cancer patients in comparison to physician' choice chemotherapy: Arm A: Carboplatin AUC (Area Under Curve) 5 d 8 q 28 Plus Decitabine 10 mg/mq iv d1-5 q 28 Arm B: Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/mq gg 1, 8, 15 q 28 Patients will be randomly assigned in a 1:1 ratio to treatment arms.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted